ERBB2 and breast carcinoma: For taselisib, studies have shown that in patients with HER2‐negative, hormone receptor‐positive advanced breast cancer, regardless of PIK3CA mutation status, the combination of taselisib and fulvestrant has clinical activity.68, 69